The MIRACLE Medical Technology Act of 2024 directs the Secretary of Health and Human Services to establish a program coordinating research and development collaboration between the United States and Israel in healthcare products and services. The program covers joint research projects, regulatory harmonization, innovation support, telemedicine development, biological product manufacturing, and disease prevention initiatives, with a focus on medical devices, pharmaceuticals, genomics, and digital health solutions. The bill authorizes $8 million annually from fiscal year 2025 through 2029 to support these efforts and requires the program to begin within six months of enactment. The collaboration involves multiple U.S. agencies including the Food and Drug Administration and Centers for Medicare and Medicaid Services working with Israel's Ministry of Health. This legislation affects healthcare companies, researchers, medical device manufacturers, and patients by potentially accelerating the development and delivery of new medical technologies through U.S.-Israeli partnerships.